<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071901</url>
  </required_header>
  <id_info>
    <org_study_id>CASE4913</org_study_id>
    <secondary_id>NCI-2014-00252</secondary_id>
    <nct_id>NCT02071901</nct_id>
  </id_info>
  <brief_title>Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy</brief_title>
  <official_title>A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well eltrombopag olamine works in improving the recovery of&#xD;
      platelet counts in older patients with Acute Myeloid Leukemia (AML) undergoing induction (the&#xD;
      first treatment given for a disease) chemotherapy. Platelet counts recover more slowly in&#xD;
      older patients, leading to risk of complications and the delay of post-remission therapy.&#xD;
      Eltrombopag olamine may cause the body to make platelets after chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I.To determine whether eltrombopag leads to early platelet recovery in older AML patients (≥&#xD;
      60years) who attain morphologic remission on day 14 (range, day 14-17) bone marrow assessment&#xD;
      following remission induction chemotherapy (IC).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the effect of eltrombopag on megakaryopoiesis - median time to reach platelet&#xD;
      count ≥50,000 /μL and ≥100,000 /μL, number of days of platelet transfusion, rates of platelet&#xD;
      transfusion-independence and the median time to reach platelet transfusion independence.&#xD;
&#xD;
      II. To determine the effect of eltrombopag on the rates of clinically significant bleeding&#xD;
      events (CSBE).&#xD;
&#xD;
      III. To determine the effect of eltrombopag on erythropoiesis the median time to red blood&#xD;
      cell transfusion independence.&#xD;
&#xD;
      IV. To determine the effect of eltrombopag on granulopoiesis- the time taken to reach an&#xD;
      absolute neutrophil count of ≥ 500 /μL. V. To determine the safety and tolerability of&#xD;
      eltrombopag in AML patients undergoing remission IC - incidence and severity of&#xD;
      eltrombopag-related adverse events. VI. To determine rates of complete remission (CR), rates&#xD;
      of partial complete remission (CRp), time to attain CR, and time to initiation of&#xD;
      post-remission consolidation therapy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive eltrombopag olamine orally (PO) once daily (QD) until platelet counts&#xD;
      reach ≥50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence&#xD;
      of unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, participants are followed up for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 14, 2014</start_date>
  <completion_date type="Anticipated">September 26, 2023</completion_date>
  <primary_completion_date type="Actual">October 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Median Platelet Count &gt;= 50,000/uL</measure>
    <time_frame>Day 24 of Treatment</time_frame>
    <description>Number of participants with a median platelet count &gt;= 50,000/uL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time Needed to Reach Platelet Count &gt;= 50,000 /µL in Days</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Defined as the average number of days from the first day of eltrombopag until the first of five consecutive days with platelet counts &gt;= 50,000 /µL without a platelet transfusion. The time will be summarized using the Kaplan-Meier method and will use the logrank test and proportional hazards models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Days of Platelet Transfusions</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Defined as the median number of days from the first day of eltrombopag until the patient stopped treatment. The time will be summarized using the Kaplan-Meier method and will use the log-rank test and proportional hazards models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Clinically Significant Bleeding Events</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The number of bleeding events experienced by patients during treatment including hematuria, gastrointestinal bleed (with or without requiring intervention, retroperitoneal bleeding, intra-cranial bleed, epistaxis not controlled by conservative measures and muscle or soft tissue hematomas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Absolute Neutrophil Recovery, Defined as &gt; 500/uL</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The average number of days patients take to reach a neutrophil count &gt;500/ul as summarized using the Kaplan-Meier method and modeled using logrank test and proportional hazards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Rise in Hemoglobin Level in Patients With Pretreatment Hemoglobin of &lt; 8 g/dL</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The median increase in hemoglobin levels in g/dL among patients with a starting hemoglobin level &lt;8g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The percent of participants with a sustained improvement of platelet counts (independent of platelet transfusions) to ≥ 50,000 /µL lasting for at least 2 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Days to Attain Complete Response</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The median number of days participants take to achieve a complete response as defined as a sustained improvement of platelet counts (independent of platelet transfusions) to ≥ 50,000 /µL lasting for at least 2 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Complete Response Rate</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The number of participants with a sustained improvement of platelet counts (independent of platelet transfusions) seen by at least a doubling of platelet count from the pretreatment thrombocytopenic level (defined as &lt; 10000 /µL, ) or an absolute increase in platelet counts to between 30000 /µL and 50000 /µL, whichever is higher but not achieving complete response. Or if there is a need to restart eltrombopag due to drop in platelet count to below 50000 /µL following interruption of eltrombopag therapy after achieving platelet counts of &gt; 100000 /µL on the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Initiation of Post-remission Therapy</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The average number of days from the the beginning of treatment to the onset of post-remission therapy as summarized using the Kaplan-Meier method and calculated using the logrank test and proportional hazards models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Refractory or Persistent Disease</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The number of participants with presence of morphologic evidence of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - Percent of Participants Alive at Follow-up</measure>
    <time_frame>at 28 days, at 6 months and up to 5 years</time_frame>
    <description>OS is defined from the day of study registration until the last follow-up or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 3/4 Adverse Events Adverse Events, Determined According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0</measure>
    <time_frame>Up to 4 weeks after last dose of eltrombopag olamine</time_frame>
    <description>Incidence of grade 3/4 adverse events (AE), determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.&#xD;
For full list, see AE/serious adverse event (SAE) section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>At 5 year follow-up</time_frame>
    <description>Calculated from the date of complete remission until relapse, the date of last follow-up, or other protocol-defined event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome</condition>
  <condition>Adult Acute Basophilic Leukemia</condition>
  <condition>Adult Acute Eosinophilic Leukemia</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Minimally Differentiated Myeloid Leukemia (M0)</condition>
  <condition>Adult Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Adult Acute Monocytic Leukemia (M5b)</condition>
  <condition>Adult Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Supportive care (eltrombopag olamine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive eltrombopag olamine by mouth (PO) daily (QD) until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eltrombopag olamine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Supportive care (eltrombopag olamine)</arm_group_label>
    <other_name>Promacta</other_name>
    <other_name>SB 497115</other_name>
    <other_name>SB-497115</other_name>
    <other_name>SB497115</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All categories of AML will be included except for acute promyelocytic leukemia (APL),&#xD;
             acute megakaryocytic leukemia, and acute leukemias of ambiguous lineage undergoing 7 +&#xD;
             3 remission IC with cytarabine and an anthracycline (daunorubicin or idarubicin). All&#xD;
             cases have to be histopathologically confirmed by a diagnostic bone marrow biopsy. Use&#xD;
             of granulocyte colony-stimulating factor (G-CSF) for any indication must have been&#xD;
             discontinued at least 7 days prior to entry into the study.&#xD;
&#xD;
          -  Patients with secondary AML arising out of Myelodysplastic syndrome (MDS) (all&#xD;
             subtypes under WHO [World Health Organization] classification), chronic myelomonocytic&#xD;
             leukemia (CMML); therapy-related AML and those with a prior autologous hematopoietic&#xD;
             cell transplantation are eligible.&#xD;
&#xD;
          -  No morphological evidence of disease on day 14 bone marrow examination following IC&#xD;
&#xD;
          -  Must be able to give voluntary informed written consent to participate in the study;&#xD;
             informed consent will be obtained prior to initiation of remission IC and before any&#xD;
             study-related procedure not part of normal medical care, with the understanding that&#xD;
             consent may be withdrawn by the subject at any time without prejudice to future&#xD;
             medical care&#xD;
&#xD;
          -  Women of childbearing potential should be advised to avoid becoming pregnant and men&#xD;
             should be advised to not father a child while receiving treatment. All men and women&#xD;
             of childbearing potential must use acceptable methods of birth control throughout the&#xD;
             study as described below:&#xD;
&#xD;
               1. Females of childbearing potential: Recommendation is for 2 effective&#xD;
                  contraceptive methods during the study. Adequate forms of contraception are&#xD;
                  double-barrier methods (condoms with spermicidal jelly or foam and diaphragm with&#xD;
                  spermicidal jelly or foam), oral, depo provera, or injectable contraceptives,&#xD;
                  intrauterine devices, and tubal ligation.&#xD;
&#xD;
               2. Male patients with female partners who are of childbearing potential:&#xD;
                  Recommendation is for male and partner to use at least 2 effective contraceptive&#xD;
                  methods, as described above, during the study or to abstain.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that, in&#xD;
             the view of the treating physician, would place the participant at an unacceptable&#xD;
             risk if he or she were to participate in the study or would prevent that person from&#xD;
             giving informed consent&#xD;
&#xD;
          -  Any active malignancy (unrelated, non-hematological malignancy) diagnosed within the&#xD;
             past 12 months of starting the study drug (other than curatively treated&#xD;
             carcinoma-in-situ of the cervix or non-melanoma skin cancer).&#xD;
&#xD;
          -  Secondary AML arising out of myeloproliferative neoplasms [as per the revised 2008 WHO&#xD;
             classification of myeloid neoplasms and acute leukemias] and MDS/myeloproliferative&#xD;
             disease (MPD) neoplasms other than CMML [as per the revised 2008 WHO classification of&#xD;
             myeloid neoplasms and acute leukemias]. Refractory Anemia with Ringed Sideroblasts&#xD;
             with thrombocytosis (RARS-T) classified as MDS/MPN neoplasm, unclassifiable will be&#xD;
             excluded. AML patients with presenting features suspicious of underlying unrecognized&#xD;
             MPD such as marked splenomegaly (&gt; 20 cm) and thrombocytosis (&gt;400,000 per microliter)&#xD;
             will be excluded. Patients with relapsed or refractory AML will be excluded.&#xD;
&#xD;
          -  Radiation therapy, cytotoxic chemotherapy, and combined modality (both radiation and&#xD;
             chemotherapy) used to treat other cancers or medical conditions and administered&#xD;
             within 12 months prior to signing informed consent. Use of hydroxyurea or emergent&#xD;
             leukapheresis (for cytoreduction of highly elevated white blood cell counts) is&#xD;
             permissible. Those AML patients who initially receive treatment with all-trans&#xD;
             retinoic acid (ATRA) for presumptive diagnosis of APL but if APL is ruled out in final&#xD;
             pathology will be eligible for the study.&#xD;
&#xD;
          -  Prior history of treatment with recombinant thrombopoietin (TPO) or TPO-receptor (R)&#xD;
             agonists&#xD;
&#xD;
          -  History of arterial or venous thrombosis [excluding line-thrombosis] within the last 1&#xD;
             year, or those with known inherited coagulopathies. Arterial or venous thrombosis&#xD;
             includes pulmonary embolism, deep vein thrombosis of both upper [excluding&#xD;
             line-thrombosis] and lower extremities, coronary artery disease managed medically or&#xD;
             requiring intervention (percutaneous stent placement or coronary bypass surgery),&#xD;
             cerebrovascular accident (for transient ischemic attacks clinical documentation is&#xD;
             required), or involvement of other organs (such as hepatic, renal, spleen or other&#xD;
             sites).&#xD;
&#xD;
          -  Evidence of fibrosis on bone marrow examination at the time of diagnosis&#xD;
&#xD;
          -  Active participation in any other investigational treatment study&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to uncontrolled&#xD;
             infection, symptomatic congestive heart failure, cardiac arrhythmia, unstable angina&#xD;
             or renal insufficiency (acute or chronic) on hemodialysis&#xD;
&#xD;
          -  Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])&#xD;
             can not be greater than or equal to 2.5 times the upper limits of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≥ 1.5 x ULN within 14 days of enrollment.&#xD;
&#xD;
          -  Serum creatinine should be ≥ 2.5 x ULN within 14 days of enrollment&#xD;
&#xD;
          -  A known immediate or delayed hypersensitivity reaction or idiosyncrasy that, in the&#xD;
             opinion of the Medical Monitor is due to drugs chemically related to eltrombopag or&#xD;
             excipients (e.g. mannitol)&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or active hepatitis B or C&#xD;
&#xD;
          -  No major surgery within 2 weeks prior to trial enrollment&#xD;
&#xD;
          -  Female subject is pregnant or breast-feeding&#xD;
&#xD;
          -  Male and female patients who are fertile who do not agree to use an effective barrier&#xD;
             methods of birth control (i.e. abstinence) to avoid pregnancy while receiving study&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudipto Mukherjee, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <results_first_submitted>September 17, 2020</results_first_submitted>
  <results_first_submitted_qc>November 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 24, 2020</results_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Basophilic, Acute</mesh_term>
    <mesh_term>Leukemia, Eosinophilic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02071901/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02071901/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Supportive Care (Eltrombopag Olamine)</title>
          <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who went on study</population>
      <group_list>
        <group group_id="B1">
          <title>Supportive Care (Eltrombopag Olamine)</title>
          <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="60" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Median Platelet Count &gt;= 50,000/uL</title>
        <description>Number of participants with a median platelet count &gt;= 50,000/uL</description>
        <time_frame>Day 24 of Treatment</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Median Platelet Count &gt;= 50,000/uL</title>
          <description>Number of participants with a median platelet count &gt;= 50,000/uL</description>
          <population>Participants who completed study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time Needed to Reach Platelet Count &gt;= 50,000 /µL in Days</title>
        <description>Defined as the average number of days from the first day of eltrombopag until the first of five consecutive days with platelet counts &gt;= 50,000 /µL without a platelet transfusion. The time will be summarized using the Kaplan-Meier method and will use the logrank test and proportional hazards models.</description>
        <time_frame>up to 12 weeks</time_frame>
        <population>Participants who completed study. Statistical tests were not completed because a) Difficulty in obtaining accurate information on the reasons for platelet transfusion in the historical cohort and b) Several participants had platelet counts higher than threshold for starting transfusion, making comparisons not meaningful</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time Needed to Reach Platelet Count &gt;= 50,000 /µL in Days</title>
          <description>Defined as the average number of days from the first day of eltrombopag until the first of five consecutive days with platelet counts &gt;= 50,000 /µL without a platelet transfusion. The time will be summarized using the Kaplan-Meier method and will use the logrank test and proportional hazards models.</description>
          <population>Participants who completed study. Statistical tests were not completed because a) Difficulty in obtaining accurate information on the reasons for platelet transfusion in the historical cohort and b) Several participants had platelet counts higher than threshold for starting transfusion, making comparisons not meaningful</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Days of Platelet Transfusions</title>
        <description>Defined as the median number of days from the first day of eltrombopag until the patient stopped treatment. The time will be summarized using the Kaplan-Meier method and will use the log-rank test and proportional hazards models.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants who completed study. Statistical tests were not completed because a) Difficulty in obtaining accurate information on the reasons for platelet transfusion in the historical cohort and b) Several participants had platelet counts higher than threshold for starting transfusion, making comparisons not meaningful</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Median Days of Platelet Transfusions</title>
          <description>Defined as the median number of days from the first day of eltrombopag until the patient stopped treatment. The time will be summarized using the Kaplan-Meier method and will use the log-rank test and proportional hazards models.</description>
          <population>Participants who completed study. Statistical tests were not completed because a) Difficulty in obtaining accurate information on the reasons for platelet transfusion in the historical cohort and b) Several participants had platelet counts higher than threshold for starting transfusion, making comparisons not meaningful</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Clinically Significant Bleeding Events</title>
        <description>The number of bleeding events experienced by patients during treatment including hematuria, gastrointestinal bleed (with or without requiring intervention, retroperitoneal bleeding, intra-cranial bleed, epistaxis not controlled by conservative measures and muscle or soft tissue hematomas.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Clinically Significant Bleeding Events</title>
          <description>The number of bleeding events experienced by patients during treatment including hematuria, gastrointestinal bleed (with or without requiring intervention, retroperitoneal bleeding, intra-cranial bleed, epistaxis not controlled by conservative measures and muscle or soft tissue hematomas.</description>
          <population>Participants who completed study</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Absolute Neutrophil Recovery, Defined as &gt; 500/uL</title>
        <description>The average number of days patients take to reach a neutrophil count &gt;500/ul as summarized using the Kaplan-Meier method and modeled using logrank test and proportional hazards.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Data not collected - daily blood counts were not checked once participants were discharged or received post-remission therapy and subsequent follow ups locally</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Absolute Neutrophil Recovery, Defined as &gt; 500/uL</title>
          <description>The average number of days patients take to reach a neutrophil count &gt;500/ul as summarized using the Kaplan-Meier method and modeled using logrank test and proportional hazards.</description>
          <population>Data not collected - daily blood counts were not checked once participants were discharged or received post-remission therapy and subsequent follow ups locally</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Rise in Hemoglobin Level in Patients With Pretreatment Hemoglobin of &lt; 8 g/dL</title>
        <description>The median increase in hemoglobin levels in g/dL among patients with a starting hemoglobin level &lt;8g/dL</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Data not collected - daily blood counts were not checked once participants were discharged or received post-remission therapy and subsequent follow ups locally</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Median Rise in Hemoglobin Level in Patients With Pretreatment Hemoglobin of &lt; 8 g/dL</title>
          <description>The median increase in hemoglobin levels in g/dL among patients with a starting hemoglobin level &lt;8g/dL</description>
          <population>Data not collected - daily blood counts were not checked once participants were discharged or received post-remission therapy and subsequent follow ups locally</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rate</title>
        <description>The percent of participants with a sustained improvement of platelet counts (independent of platelet transfusions) to ≥ 50,000 /µL lasting for at least 2 weeks.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate</title>
          <description>The percent of participants with a sustained improvement of platelet counts (independent of platelet transfusions) to ≥ 50,000 /µL lasting for at least 2 weeks.</description>
          <population>Participants who completed study</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Days to Attain Complete Response</title>
        <description>The median number of days participants take to achieve a complete response as defined as a sustained improvement of platelet counts (independent of platelet transfusions) to ≥ 50,000 /µL lasting for at least 2 weeks.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Median Days to Attain Complete Response</title>
          <description>The median number of days participants take to achieve a complete response as defined as a sustained improvement of platelet counts (independent of platelet transfusions) to ≥ 50,000 /µL lasting for at least 2 weeks.</description>
          <population>Participants who completed study</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="25" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Complete Response Rate</title>
        <description>The number of participants with a sustained improvement of platelet counts (independent of platelet transfusions) seen by at least a doubling of platelet count from the pretreatment thrombocytopenic level (defined as &lt; 10000 /µL, ) or an absolute increase in platelet counts to between 30000 /µL and 50000 /µL, whichever is higher but not achieving complete response. Or if there is a need to restart eltrombopag due to drop in platelet count to below 50000 /µL following interruption of eltrombopag therapy after achieving platelet counts of &gt; 100000 /µL on the drug.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Complete Response Rate</title>
          <description>The number of participants with a sustained improvement of platelet counts (independent of platelet transfusions) seen by at least a doubling of platelet count from the pretreatment thrombocytopenic level (defined as &lt; 10000 /µL, ) or an absolute increase in platelet counts to between 30000 /µL and 50000 /µL, whichever is higher but not achieving complete response. Or if there is a need to restart eltrombopag due to drop in platelet count to below 50000 /µL following interruption of eltrombopag therapy after achieving platelet counts of &gt; 100000 /µL on the drug.</description>
          <population>Participants who completed study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Initiation of Post-remission Therapy</title>
        <description>The average number of days from the the beginning of treatment to the onset of post-remission therapy as summarized using the Kaplan-Meier method and calculated using the logrank test and proportional hazards models.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Data not collected - daily blood counts were not checked once participants were discharged or received post-remission therapy and subsequent follow ups locally</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Initiation of Post-remission Therapy</title>
          <description>The average number of days from the the beginning of treatment to the onset of post-remission therapy as summarized using the Kaplan-Meier method and calculated using the logrank test and proportional hazards models.</description>
          <population>Data not collected - daily blood counts were not checked once participants were discharged or received post-remission therapy and subsequent follow ups locally</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Refractory or Persistent Disease</title>
        <description>The number of participants with presence of morphologic evidence of disease</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Refractory or Persistent Disease</title>
          <description>The number of participants with presence of morphologic evidence of disease</description>
          <population>Participants who completed study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) - Percent of Participants Alive at Follow-up</title>
        <description>OS is defined from the day of study registration until the last follow-up or death</description>
        <time_frame>at 28 days, at 6 months and up to 5 years</time_frame>
        <population>Participants who went on study</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) - Percent of Participants Alive at Follow-up</title>
          <description>OS is defined from the day of study registration until the last follow-up or death</description>
          <population>Participants who went on study</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days from start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months from start of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 3/4 Adverse Events Adverse Events, Determined According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0</title>
        <description>Incidence of grade 3/4 adverse events (AE), determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.&#xD;
For full list, see AE/serious adverse event (SAE) section</description>
        <time_frame>Up to 4 weeks after last dose of eltrombopag olamine</time_frame>
        <population>Participants enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>Supportive Care (Eltrombopag Olamine)</title>
            <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 3/4 Adverse Events Adverse Events, Determined According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0</title>
          <description>Incidence of grade 3/4 adverse events (AE), determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.&#xD;
For full list, see AE/serious adverse event (SAE) section</description>
          <population>Participants enrolled in study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>febrile neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>thromboembolic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>generalized myalgias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypokalemia &amp; hypocalhypokalemia &amp; hypocalcemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-Free Survival</title>
        <description>Calculated from the date of complete remission until relapse, the date of last follow-up, or other protocol-defined event</description>
        <time_frame>At 5 year follow-up</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected for 4 weeks post intervention and mortality is monitored for up to 5 years of follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Supportive Care (Eltrombopag Olamine)</title>
          <description>Patients receive eltrombopag olamine PO QD until platelet counts reach &gt;= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.&#xD;
eltrombopag olamine: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Blood infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sudipto Mukherjee</name_or_title>
      <organization>Cleveland Clinic, Case Comprehensive Cancer Center</organization>
      <phone>1-866-223-8100</phone>
      <email>TaussigResearch@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

